223 related articles for article (PubMed ID: 29192388)
1. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance.
Hammerlindl H; Schaider H
J Cell Commun Signal; 2018 Mar; 12(1):133-141. PubMed ID: 29192388
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics and metabolism at the crossroads of stress-induced plasticity, stemness and therapeutic resistance in cancer.
Ravindran Menon D; Hammerlindl H; Torrano J; Schaider H; Fujita M
Theranostics; 2020; 10(14):6261-6277. PubMed ID: 32483452
[TBL] [Abstract][Full Text] [Related]
3. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy.
Lim ZF; Ma PC
J Hematol Oncol; 2019 Dec; 12(1):134. PubMed ID: 31815659
[TBL] [Abstract][Full Text] [Related]
4. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.
Tulchinsky E; Demidov O; Kriajevska M; Barlev NA; Imyanitov E
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):29-39. PubMed ID: 30419315
[TBL] [Abstract][Full Text] [Related]
5. The great escape: tumour cell plasticity in resistance to targeted therapy.
Boumahdi S; de Sauvage FJ
Nat Rev Drug Discov; 2020 Jan; 19(1):39-56. PubMed ID: 31601994
[TBL] [Abstract][Full Text] [Related]
6. Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer.
Cabanos HF; Hata AN
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071428
[TBL] [Abstract][Full Text] [Related]
7. Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer.
Leonce C; Saintigny P; Ortiz-Cuaran S
Mol Cancer Res; 2022 Jan; 20(1):11-29. PubMed ID: 34389691
[TBL] [Abstract][Full Text] [Related]
8. Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma.
Fattore L; Mancini R; Ciliberto G
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33202944
[TBL] [Abstract][Full Text] [Related]
9. Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.
Torrano J; Al Emran A; Hammerlindl H; Schaider H
Clin Epigenetics; 2019 Mar; 11(1):43. PubMed ID: 30850015
[TBL] [Abstract][Full Text] [Related]
10. The epigenome and the many facets of cancer drug tolerance.
Moore PC; Henderson KW; Classon M
Adv Cancer Res; 2023; 158():1-39. PubMed ID: 36990531
[TBL] [Abstract][Full Text] [Related]
11. Persister cell plasticity in tumour drug resistance.
McDonald PC; Dedhar S
Semin Cell Dev Biol; 2024 Mar; 156():1-10. PubMed ID: 37977107
[TBL] [Abstract][Full Text] [Related]
12. The emergence of drug resistance to targeted cancer therapies: Clinical evidence.
Sarmento-Ribeiro AB; Scorilas A; Gonçalves AC; Efferth T; Trougakos IP
Drug Resist Updat; 2019 Dec; 47():100646. PubMed ID: 31733611
[TBL] [Abstract][Full Text] [Related]
13. Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies.
Diazzi S; Tartare-Deckert S; Deckert M
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32466585
[TBL] [Abstract][Full Text] [Related]
14. Stochastic population dynamics of cancer stemness and adaptive response to therapies.
Jain P; Duddu AS; Jolly MK
Essays Biochem; 2022 Sep; 66(4):387-398. PubMed ID: 36073715
[TBL] [Abstract][Full Text] [Related]
15. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer.
Angus SP; Zawistowski JS; Johnson GL
Annu Rev Pharmacol Toxicol; 2018 Jan; 58():209-229. PubMed ID: 28934561
[TBL] [Abstract][Full Text] [Related]
17. New Insights into the Phenotype Switching of Melanoma.
Pagliuca C; Di Leo L; De Zio D
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551603
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.
Thiagarajan PS; Wu X; Zhang W; Shi I; Bagai R; Leahy P; Feng Y; Veigl M; Lindner D; Danielpour D; Yin L; Rosell R; Bivona TG; Zhang Z; Ma PC
Oncotarget; 2016 Dec; 7(50):82013-82027. PubMed ID: 27852038
[TBL] [Abstract][Full Text] [Related]
19. Adaptive resistance to targeted therapies in cancer.
Rosell R; Karachaliou N; Morales-Espinosa D; Costa C; Molina MA; Sansano I; Gasco A; Viteri S; Massuti B; Wei J; González Cao M; Martínez Bueno A
Transl Lung Cancer Res; 2013 Jun; 2(3):152-9. PubMed ID: 25806228
[TBL] [Abstract][Full Text] [Related]
20. Group Behavior and Emergence of Cancer Drug Resistance.
Bhattacharya S; Mohanty A; Achuthan S; Kotnala S; Jolly MK; Kulkarni P; Salgia R
Trends Cancer; 2021 Apr; 7(4):323-334. PubMed ID: 33622644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
